Tolerability and efficacy of a three-age class dosage schedule of Diethylcarbamazine citrate (DEC) in the treatment of microfilaria carriers of Wuchereria bancrofti and its implications in mass drug administration (MDA) strategy for elimination of lymphatic filariasis (LF).
Identifieur interne : 007E47 ( Main/Exploration ); précédent : 007E46; suivant : 007E48Tolerability and efficacy of a three-age class dosage schedule of Diethylcarbamazine citrate (DEC) in the treatment of microfilaria carriers of Wuchereria bancrofti and its implications in mass drug administration (MDA) strategy for elimination of lymphatic filariasis (LF).
Auteurs : S P Pani ; L K Das ; P. VanamailSource :
- The Journal of communicable diseases [ 0019-5138 ] ; 2005.
Descripteurs français
- KwdFr :
- Adolescent, Animaux, Diéthylcarbamazine (administration et posologie), Diéthylcarbamazine (effets indésirables), Diéthylcarbamazine (usage thérapeutique), Enfant, Enfant d'âge préscolaire, Facteurs de l'âge, Filaricides (administration et posologie), Filaricides (effets indésirables), Filaricides (usage thérapeutique), Filariose lymphatique (), Humains, Nourrisson, Porteur sain (traitement médicamenteux), Wuchereria bancrofti (pathogénicité).
- MESH :
- administration et posologie : Diéthylcarbamazine, Filaricides.
- effets indésirables : Diéthylcarbamazine, Filaricides.
- pathogénicité : Wuchereria bancrofti.
- traitement médicamenteux : Porteur sain.
- usage thérapeutique : Diéthylcarbamazine, Filaricides.
- Adolescent, Animaux, Enfant, Enfant d'âge préscolaire, Facteurs de l'âge, Filariose lymphatique, Humains, Nourrisson.
English descriptors
- KwdEn :
- Adolescent, Age Factors, Animals, Carrier State (drug therapy), Child, Child, Preschool, Diethylcarbamazine (administration & dosage), Diethylcarbamazine (adverse effects), Diethylcarbamazine (therapeutic use), Elephantiasis, Filarial (prevention & control), Filaricides (administration & dosage), Filaricides (adverse effects), Filaricides (therapeutic use), Humans, Infant, Wuchereria bancrofti (pathogenicity).
- MESH :
- chemical , administration & dosage : Diethylcarbamazine, Filaricides.
- chemical , adverse effects : Diethylcarbamazine, Filaricides.
- drug therapy : Carrier State.
- pathogenicity : Wuchereria bancrofti.
- prevention & control : Elephantiasis, Filarial.
- chemical , therapeutic use : Diethylcarbamazine, Filaricides.
- Adolescent, Age Factors, Animals, Child, Child, Preschool, Humans, Infant.
Abstract
A six-age class dosage schedule of Diethylcarbamazine (DEC) of 50mg (1-2 years), 100mg (3-4 years), 150mg (5-8 years), 200mg (9-11 years), 250mg (12-14 years) and 300mg for above 14 years is being adopted for annual single dose MDA for LF elimination treat Wuchereria bancrofti microfilaria carriers. In order to increase the community compliance as well as to make the distribution easier during MDA, a revised 3 age class dosage schedule of 100mg (2-4 years), 200mg (5-14 years) and 300mg for above 14 years was evaluated for its tolerability and efficacy. By this change, it was observed that the 4-8 years age class is receiving 50 mg higher and 11-14 years age class is receiving 50mg lesser dose compared to the earlier class schedule. Therefore, the safety aspect in the age class of 4-8 years and efficacy component in the age class of 11-14 years were assessed. Apparently "healthy" asymptomatic microfilaraemic volunteers between the age class of 4-8 and 11-14 years were recruited for the study. The incidence of side reaction in the 4-8 years age class was 50.0% with 150mg dose and 66.7% with 200mg (P>0.05). No life threatening adverse reactions was observed in any dosage schedule. Fever, headache and myalgia, the predominant adverse reactions were mild and similar in both schedules. The mean intensity of the three major specific adverse reactions (fever, headache and myalgia) also did not differ significantly (P>0.05). For the purpose of LF elimination, efficacy in terms of reduction in mean microfilaria load is important. In the 11-14 year age class considerable reduction in the geometric mean density (GMD) was observed by day 90 and 180 post-therapy in both groups (250mg group and 200mg group) compared to pre-therapy level. By day 360 post-therapy, the difference was statistically not significant (P>0.05) (reduction of 72.2% in 250mg and 69.6% reduction in 200mg). The reductions in GMD were statistically significant when compared to pre-therapy levels in both the old (250mg) and new (200mg) doses. Thus, three- age class dosage schedule is as safe and efficacious as the six- age class schedule.
PubMed: 16637395
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 003A16
- to stream PubMed, to step Curation: 003A16
- to stream PubMed, to step Checkpoint: 003A16
- to stream Ncbi, to step Merge: 002205
- to stream Ncbi, to step Curation: 002205
- to stream Ncbi, to step Checkpoint: 002205
- to stream Main, to step Merge: 008048
- to stream Main, to step Curation: 007E47
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tolerability and efficacy of a three-age class dosage schedule of Diethylcarbamazine citrate (DEC) in the treatment of microfilaria carriers of Wuchereria bancrofti and its implications in mass drug administration (MDA) strategy for elimination of lymphatic filariasis (LF).</title><author><name sortKey="Pani, S P" sort="Pani, S P" uniqKey="Pani S" first="S P" last="Pani">S P Pani</name><affiliation><nlm:affiliation>Vector Control Research Centre (Indian Council of Medical Research), Pondicherry.</nlm:affiliation><wicri:noCountry code="subField">Pondicherry</wicri:noCountry></affiliation></author><author><name sortKey="Das, L K" sort="Das, L K" uniqKey="Das L" first="L K" last="Das">L K Das</name></author><author><name sortKey="Vanamail, P" sort="Vanamail, P" uniqKey="Vanamail P" first="P" last="Vanamail">P. Vanamail</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:16637395</idno><idno type="pmid">16637395</idno><idno type="wicri:Area/PubMed/Corpus">003A16</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003A16</idno><idno type="wicri:Area/PubMed/Curation">003A16</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003A16</idno><idno type="wicri:Area/PubMed/Checkpoint">003A16</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">003A16</idno><idno type="wicri:Area/Ncbi/Merge">002205</idno><idno type="wicri:Area/Ncbi/Curation">002205</idno><idno type="wicri:Area/Ncbi/Checkpoint">002205</idno><idno type="wicri:doubleKey">0019-5138:2005:Pani S:tolerability:and:efficacy</idno><idno type="wicri:Area/Main/Merge">008048</idno><idno type="wicri:Area/Main/Curation">007E47</idno><idno type="wicri:Area/Main/Exploration">007E47</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Tolerability and efficacy of a three-age class dosage schedule of Diethylcarbamazine citrate (DEC) in the treatment of microfilaria carriers of Wuchereria bancrofti and its implications in mass drug administration (MDA) strategy for elimination of lymphatic filariasis (LF).</title><author><name sortKey="Pani, S P" sort="Pani, S P" uniqKey="Pani S" first="S P" last="Pani">S P Pani</name><affiliation><nlm:affiliation>Vector Control Research Centre (Indian Council of Medical Research), Pondicherry.</nlm:affiliation><wicri:noCountry code="subField">Pondicherry</wicri:noCountry></affiliation></author><author><name sortKey="Das, L K" sort="Das, L K" uniqKey="Das L" first="L K" last="Das">L K Das</name></author><author><name sortKey="Vanamail, P" sort="Vanamail, P" uniqKey="Vanamail P" first="P" last="Vanamail">P. Vanamail</name></author></analytic><series><title level="j">The Journal of communicable diseases</title><idno type="ISSN">0019-5138</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Age Factors</term><term>Animals</term><term>Carrier State (drug therapy)</term><term>Child</term><term>Child, Preschool</term><term>Diethylcarbamazine (administration & dosage)</term><term>Diethylcarbamazine (adverse effects)</term><term>Diethylcarbamazine (therapeutic use)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Filaricides (administration & dosage)</term><term>Filaricides (adverse effects)</term><term>Filaricides (therapeutic use)</term><term>Humans</term><term>Infant</term><term>Wuchereria bancrofti (pathogenicity)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term><term>Animaux</term><term>Diéthylcarbamazine (administration et posologie)</term><term>Diéthylcarbamazine (effets indésirables)</term><term>Diéthylcarbamazine (usage thérapeutique)</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Facteurs de l'âge</term><term>Filaricides (administration et posologie)</term><term>Filaricides (effets indésirables)</term><term>Filaricides (usage thérapeutique)</term><term>Filariose lymphatique ()</term><term>Humains</term><term>Nourrisson</term><term>Porteur sain (traitement médicamenteux)</term><term>Wuchereria bancrofti (pathogénicité)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Diéthylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Carrier State</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Diéthylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Wuchereria bancrofti</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Diethylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Porteur sain</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Diéthylcarbamazine</term><term>Filaricides</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Age Factors</term><term>Animals</term><term>Child</term><term>Child, Preschool</term><term>Humans</term><term>Infant</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Animaux</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Facteurs de l'âge</term><term>Filariose lymphatique</term><term>Humains</term><term>Nourrisson</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A six-age class dosage schedule of Diethylcarbamazine (DEC) of 50mg (1-2 years), 100mg (3-4 years), 150mg (5-8 years), 200mg (9-11 years), 250mg (12-14 years) and 300mg for above 14 years is being adopted for annual single dose MDA for LF elimination treat Wuchereria bancrofti microfilaria carriers. In order to increase the community compliance as well as to make the distribution easier during MDA, a revised 3 age class dosage schedule of 100mg (2-4 years), 200mg (5-14 years) and 300mg for above 14 years was evaluated for its tolerability and efficacy. By this change, it was observed that the 4-8 years age class is receiving 50 mg higher and 11-14 years age class is receiving 50mg lesser dose compared to the earlier class schedule. Therefore, the safety aspect in the age class of 4-8 years and efficacy component in the age class of 11-14 years were assessed. Apparently "healthy" asymptomatic microfilaraemic volunteers between the age class of 4-8 and 11-14 years were recruited for the study. The incidence of side reaction in the 4-8 years age class was 50.0% with 150mg dose and 66.7% with 200mg (P>0.05). No life threatening adverse reactions was observed in any dosage schedule. Fever, headache and myalgia, the predominant adverse reactions were mild and similar in both schedules. The mean intensity of the three major specific adverse reactions (fever, headache and myalgia) also did not differ significantly (P>0.05). For the purpose of LF elimination, efficacy in terms of reduction in mean microfilaria load is important. In the 11-14 year age class considerable reduction in the geometric mean density (GMD) was observed by day 90 and 180 post-therapy in both groups (250mg group and 200mg group) compared to pre-therapy level. By day 360 post-therapy, the difference was statistically not significant (P>0.05) (reduction of 72.2% in 250mg and 69.6% reduction in 200mg). The reductions in GMD were statistically significant when compared to pre-therapy levels in both the old (250mg) and new (200mg) doses. Thus, three- age class dosage schedule is as safe and efficacious as the six- age class schedule.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Das, L K" sort="Das, L K" uniqKey="Das L" first="L K" last="Das">L K Das</name><name sortKey="Pani, S P" sort="Pani, S P" uniqKey="Pani S" first="S P" last="Pani">S P Pani</name><name sortKey="Vanamail, P" sort="Vanamail, P" uniqKey="Vanamail P" first="P" last="Vanamail">P. Vanamail</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 007E47 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 007E47 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:16637395
|texte= Tolerability and efficacy of a three-age class dosage schedule of Diethylcarbamazine citrate (DEC) in the treatment of microfilaria carriers of Wuchereria bancrofti and its implications in mass drug administration (MDA) strategy for elimination of lymphatic filariasis (LF).
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16637395" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |